- Novartis launched this new Netflix-style hub just three months ago and will run as a three-year pilot.
- It works as personalized educational videos aimed specifically at rheumatologists and is known as PEAK (Personalized Education and Knowledge).
- The service talks about more than just drugs, it talks about topics like clinical trial design, health care disparities, etc.
Novartis continues its digital push under CEO Vas Narasimhan with a new approach to the style of Netflix to help connect with doctors.
This new service, provided by the software company evermed, works like personalized educational videos specifically aimed at rheumatologists and is known as PEAK (Personalized Education and Knowledge).
Personalization is key: the great pharmaceutical industry Switzerland seeks to go beyond the traditional digital marketing foray. Which, includes webinarsemail campaigns, doctor portals, and generic YouTube medical videos, to this personalized, on-demand video/audio service.
The content is created by Novartis with rheumatologists and other health professionals to offer. What they consider, the best video service for practicing rheumatologists in the field.
Service speaks more than just medicinestalks about topics like clinical trial design, health care disparities, etc., and, of course, the rheumatology drug from NovartisCosentyx, is one of the main reasons why the pharmaceutical company is attractive to rheumatologists.
The videos have a maximum duration of 15 minutes
The videos have a maximum duration of 15 minutes, but are generally short-form content of about three minutes long with a large number of offers: mini-docuseries, vignettes, podcasts and animation videos. There are already around 90 such assets available to use.
Novartis launched this new center just three months ago and will run as a three-year pilot program. The company will need “a few months” to your credit to really measure success. But while it started with rheumatologists, the pharmaceutical industry may well expand into other areas if this works out.
Horwood said they’re already seeing stakeholders “engaging with all kinds of content,” whether it’s podcasts or videos, though “video is the most engaging” in terms of usage so far.
start in rheumatology at the new novartis center It makes sense considering that Cosentyx was Novartis’ best-selling drug last year with $4.7 billion in sales. That was a healthy 17% increase in 2020. The drug has multiple licenses, including for psoriatic arthritis and ankylosing spondylitis.
Cosentyx competes with a number of other medicines top sellers in this space, including AbbVie’s Humira, Skyrizi and Rinvoq franchises. As well as Stelara from Johnson & Johnson and Xeljanz from Pfizer. Standing out from the crowd in terms of marketing is a must in such a crowded but high-performing market space, and Novartis hopes that this on-demand service, the first of its kind in the rheumatology space, help you do just that.
Related Notes:
“The guard is calm” A PROHIBITED phrase in medical guards, here is why…
Death of the patient: the 5 stages of grief and how to face them
The 8 diseases in which Mexicans spend the most